Neuropsychobiology

Original Paper

Association between Apolipoprotein E ε4 and Longitudinal Cognitive Decline: Nested Case-Control Study among Chinese Community-Dwelling Elders

Ma F. · Wang J. · Miao R. · Zhao W. · Wang Q.

Author affiliations

Department of Epidemiology, School of Public Health, Tianjin Medical University, Tianjin, China

Keywords: Alzheimer’s diseaseApolipoprotein E ε4Cognitive declineNested case-control study

Related Articles for ""
Neuropsychobiology 2011;64:102–109
https://doi.org/10.1159/000324991

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: June 24, 2009
Accepted: January 23, 2011
Published online: June 21, 2011
Issue release date: June 2011

Number of Print Pages: 8
Number of Figures: 0
Number of Tables: 3

ISSN: 0302-282X (Print)
eISSN: 1423-0224 (Online)

For additional information: https://www.karger.com/NPS

Abstract

Background/Aims: Cognitive decline in the elderly is an early predictor of dementia. The apolipoprotein E (APOE) Ε4 allele is considered an important genetic determinant of Alzheimer’s disease (AD), and strongly suspected to play a role in cognitive variation. However, its effects upon predicting the progression of cognitive decline more generally remain unclear. Our aim was to explore the role of APOE Ε4 in longitudinal cognitive decline, considering sociodemographics, vascular disease, and lipid profile. Methods: We chose a nested case-control design, and prospectively collected demographic and clinical data, determined APOE genotypes, and obtained follow-up information on cognitive variation (measured by a spectrum of cognitive tests) for 3 years. Cognitive decline was predefined as an increase in Clinical Dementia Rating Scale class, or at least a 4-point decrease (>1 SD) in MMSE, between baseline and follow-ups. Results: Among 600 follow-up subjects with mild cognitive impairment and aged 65 years or older, 114 pairs of cognitive decline and stable subjects were identified and matched for sex, age, and educational level in a 1:1 ratio. The APOE Ε4 frequency in the cognitive decline group was significantly higher than that in the stable group (p < 0.05), while the APOE Ε2 and Ε3 prevalence in the cognitive decline group did not differ significantly from that in controls (p > 0.05). At the first follow-up, modest but significant declines only in the memory domain were associated with APOE Ε4. At the last follow-up, significant associations were noted between APOE Ε4 and cognitive decline from 5 of the 6 cognitive outcomes, which included story recall, memory, spatial recognition, naming, and sustained attention. Conditional logistic regression showed that the presence of APOE Ε4 was significantly associated with the cognitive decline group, as compared to the stable group, adjusting for vascular diseases and lipid profile. Conclusions: APOE Ε4 offered information on the risk of cognitive decline in this longitudinal study, and may exert detectable effects early in a long prodromal AD trajectory.

© 2011 S. Karger AG, Basel



Related Articles:

References

  1. Michaelson D: Apolipoprotein E4:the most prevalent yet understudied genetic risk factor of Alzheimer’s disease. Alzheimers 2008;4:149.
    External Resources
  2. Ertekin-Taner N: Genetics of Alzheimer’s disease: a centennial review. Neurol Clin 2007;25:611–667.
    External Resources
  3. Goldbourt U, Schnaider-Beeri M, Davidson M: Socioeconomic status in relationship to death of vascular disease and late-life dementia. J Neurol Sci 2007;257:177–181.
    External Resources
  4. Gomez-Tortosa E, Barquero S, Baron M, Ros R, Manzano S, Sainz M, Almaraz C, Gomez-Garre P, Jimenez-Escrig A: Apolipoprotein E genotype and variability in age at onset in sib-pairs with familial Alzheimer’s disease. Alzheimers Dementia 2006;2:S189–S190.
    External Resources
  5. Roberta Perri, Laura Serra, Giovanni Augusto Carlesimo, Carlo Caltagirone: Amnestic mild cognitive impairment: difference of memory profile in subjects who converted or did not convert to Alzheimer’s disease. Neuropsychology 2007;21:549–558.
    External Resources
  6. Choi MS, Lee JH: Biopsy-proven young-onset Alzheimer’s disease with parkinsonism. Alzheimers Dementia 2006;2:S262.
    External Resources
  7. Cho H, Kwan J, Yoon B: The effect of inhibitors of acetylcholinesterase on gait functions in Alzheimer’s disease and mild cognitive impairment. Parkinsonism Relat Dis 2008;14:S72.
    External Resources
  8. Tupler LA, Krishnan KR, Greenberg DL, Marcovina SM, Payne ME, MacFall JR, Charles HC, Doraiswamy PM: Predicting memory decline in normal elderly: Genetics, MRI, and cognitive reserve. Neurobiol Aging 2007;28:1644–1656.
    External Resources
  9. DeCoteau WE, Jurado A, Dudzic E: The relationship between hypertension and Alzheimer’s disease. Am J Hypertens 1999;2:198.
    External Resources
  10. Reiss AB, Siller KA, Rahman MM, Chan E, Ghiso J, de Leon M: Cholesterol in neurologic disorders of the elderly: stroke and Alzheimer’s disease. Neurobiol Aging 2004;25:977–989.
    External Resources
  11. Xu W, Qiu C, Winblad B, Fratiglioni L: Borderline diabetes mellitus and risk of dementia and Alzheimer disease: A population-based longitudinal study. Alzheimers Dementia 2006;2:S153.
    External Resources
  12. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B: Current concepts in mild cognitive impairment. Arch Neurol 2001;58:1985–1992.
    External Resources
  13. Mungas D, Marshall SC, Weldon M, Haan M, Reed BR: Age and education correction of the Mini-Mental State Examination for English and Spanish speaking elderly. Neurology 1996;46:700–706.
    External Resources
  14. Jorm AF, Jacomb PA: The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): socio-demographic correlates, reliability, validity and some norms. Psychol Med 1989;19:1015–1022.
    External Resources
  15. Ng TP, Niti M, Chiam PC, Kua EH: Ethnic and educational differences in cognitive test performance on Mini-Mental State Examination in Asians. Am J Geriatr Psychiatry 2007;15:130–139.
    External Resources
  16. Kalmijn S, Feskens EJ, Kromhout D: Cerebrovascular disease, the apolipoprotein e4 allele, and cognitive decline in a community-based study of elderly men. Stroke 1996;27:2230–2235.
    External Resources
  17. Howieson DB, Holm LA, Kaye JA, Oken BS, Howieson J: Neurologic function in the optimally healthy oldest old: neuropsychological evaluation. Neurology 1993;43:1882–1886.
    External Resources
  18. Moss M, Albert MS, Butters N: Differential patterns of memory loss among patients with Alzheimer’s disease, Huntington’s disease and alcoholic Korskoff’s syndrome. Arch Neurol 1986;43:239–246.
    External Resources
  19. Kaplan E, Goodglass H, Weintraub S: The Boston Naming Test and scoring booklet; in Goodglass H, Kaplan E (eds): The Assessment of Aphasia and Related Disorders, ed 2. Philadelphia, Lea & Febiger, 1983.
  20. Inouye SK, Albert MS, Mohs R, Sun K, Berkman LF: Cognitive performance in a high functioning community dwelling elderly population. Gerontology 1993;4:M146–M151.
  21. Lezak MD: Neuropsychological Assessment, ed 3. New York, Oxford University Press, 1995.
  22. Radloff LS: The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Measurement 1977;1:385–401.
    External Resources
  23. Woo J, Ho SC, Chan SG, Sham A, Yuen YK, Masarei JL: Lipid profile in the Chinese old-old: comparison with younger age groups and relationship with some cardiovascular risk factors and presence of diseases. Cardiology 1993;83:407–414.
    External Resources
  24. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Third Report of the NCEP Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143–3421.
    External Resources
  25. Tang MX, Stern Y, Marder K: The APOE-ε4 allele and the risk of Alzheimer disease among African Americans, Whites, and Hispanics. JAMA 1998;279:751–755.
    External Resources
  26. Ertekin-Taner N: Genetics of Alzheimer’s Disease: a centennial review. Neurologic Clin 2007;25:611–667.
    External Resources
  27. Albert SM, Gurland B, Maestre G, Jacobs DM, Stern Y, Mayeux R: APOE genotype influences functional status among elderly without dementia. Am J Med Ethics 1995;60:583–587.
    External Resources
  28. Fillenbaum GG, Landerman LR, Blazer DG, Saunders AM, Harris TB, Launer LJ: The relationship of APOE genotype to cognitive functioning in African American and White community resident elderly. J Am Geriatr Soc 2001;49:1148–1155.
    External Resources
  29. Albert MS, Kenneth J, Savage Cary R, Berkman L, Seeman T, Blazer D, Rowe JW: Predictors of cognitive change in older persons: MacArthur Studies of Successful Aging. Psychol Aging 1995;10:294–303.
    External Resources
  30. Zannis VI, Breslow JL: Human VLDL apoE isoprotein polymorphism is explained by genetic variation and post-translational modification. Biochemistry 1981;20:1033–1041.
    External Resources
  31. Weisgraber KH, Rall SC Jr, Mehley RW: Human E apoprotein heterogeneity: cysteine-arginine interchanges in the amino acid sequence of the apoE isoforms J Biol Chem 1981;256:9077–9083.
  32. Strittmatter WJ, Roses AD: Apolipoprotein E and Alzheimer’s disease. Annu Rev Neurosci 1996;19:53–77.
    External Resources
  33. Shigeji N, Kaori M, Nobuhiro Y: Apolipoprotein E genotype and Alzheimer’s disease. Lancet 1993;42:737.
  34. Altstiel LD, Greenberg DA, Marin D: Apolipoprotein E genotype and cognition in the very old. Lancet 1997;349:1451.
    External Resources
  35. Blair CK, Folsom AR, Knopman DS: Atherosclerosis Risk in Communities (ARIC) Study Investigators: APOE genotype and cognitive decline in a middle-aged cohort. Neurology 2005;64:268–276.
    External Resources
  36. Bunce D, Fratiglioni L, Small BJ, Winblad B, Backman L: APOE and cognitive decline in preclinical Alzheimer disease and non-demented aging. Neurology 2004;63:816–821.
    External Resources
  37. Jones S, Laukka EJ, Small BJ, Fratiglioni L, Bäckman L: A preclinical phase in vascular dementia: cognitive impairment three years before diagnosis. Dement Geriatr Cogn Disord 2004;18:233–239.
    External Resources
  38. Chen P, Ratcliff G, Belle SH, Cauley JA, DeKosky ST, Ganguli M: Patterns of cognitive decline in presymptomatic Alzheimer disease: a prospective community study. Arch Gen Psychiatry 2001;58:853–858.
    External Resources
  39. Bretsky P, Guralnik JM, Launer L, Albert M, Seeman TE: The role of APOE-ε4 in longitudinal cognitive decline. Neurology 2003;60:1077–1081.
    External Resources
  40. Kim KW, Youn JC, Jhoo JH, Lee DY, Lee KU, Lee JH, Woo JI: Apolipoprotein E epsilon 4 allele is not associated with the cognitive impairment in community-dwelling normal elderly individuals. Int J Geriatr Psychiatry 2002;17:635–640.
    External Resources
  41. Peila R, White LR, Petrovich H, Masaki K, Ross GW, Havlik RJ, Launer LJ: Joint effect of the APOE gene and midlife systolic blood pressure on late-life cognitive impairment: the Honolulu-Asia Aging Study. Stroke 2001;32:2882–2889.
    External Resources
  42. Slooter AJ, van Duijn CM, Bots ML, Ott A, Breteler MB, De Voecht J, Wehnert A, de Knijff P, Havekes LM, Grobbee DE, Van Broeckhoven C, Hofman A: Apolipoprotein E genotype, atherosclerosis, and cognitive decline: the Rotterdam Study. J Neural Transm Suppl 1998;53:17–29.
    External Resources
  43. Skoog I, Hesse C, Aevarsson O, Landahl S, Wahlstrom J, Fredman P, Blennow K: A population study of apoE genotype at the age of 85:relation to dementia, cerebrovascular disease, and mortality. J Neurosurg Psychiartry 1998;64:37–43.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: June 24, 2009
Accepted: January 23, 2011
Published online: June 21, 2011
Issue release date: June 2011

Number of Print Pages: 8
Number of Figures: 0
Number of Tables: 3

ISSN: 0302-282X (Print)
eISSN: 1423-0224 (Online)

For additional information: https://www.karger.com/NPS

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2011, Vol.64, No. 2

June 2011

Article

Recommend This
TOP